Skip to main content
Top
Published in: Inflammation Research 11/2011

01-11-2011 | Original Research Paper

Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease

Authors: Jakub Kwieciński, Elisabet Josefsson, Tao Jin

Published in: Inflammation Research | Issue 11/2011

Login to get access

Abstract

Objective

Down-regulation of fibrinolysis and increased fibrin deposition in joints are hallmarks of rheumatoid arthritis (RA), and are believed to be involved in disease progression. The mouse model of collagen-induced arthritis (CIA) closely resembles RA and has been used to explore mechanism and treatments of RA, but neither the fibrinolytic system nor pro-fibrinolytic therapies were investigated in CIA.

Materials and methods

Plasmin activity, levels of plasminogen activator inhibitor (PAI-1), D-dimer, and IL-6 were measured in plasma of CIA mice. Fibrin deposition and PAI-1 levels were also measured in inflamed joints. Mice were treated with plasminogen activators uPA (urokinase-type plasminogen activator) or tPA (tissue-type plasminogen activator). Effects of treatment on disease severity and fibrinolytic system were assessed.

Results

CIA caused decrease in plasmin activity, accompanied by increase in PAI-1 levels, in both blood and inflamed joints. This resulted in massive fibrin deposition in synovium. PAI-1 levels correlated negatively with plasmin activity and positively with IL-6. Treatments with uPA and tPA improved plasmin activity and removed fibrin deposits in inflamed joints. However, disease severity remained unchanged.

Conclusions

Fibrinolytic changes in CIA parallel changes in RA, making CIA a suitable model to study fibrinolysis in RA. Normalization of plasmin activity in CIA after treatment with plasminogen activators had no effect on disease severity.
Literature
3.
go back to reference Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis. 1992;51(8):965–8.PubMedCrossRef Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis. 1992;51(8):965–8.PubMedCrossRef
4.
go back to reference Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis. 1997;56(9):550–7.PubMedCrossRef Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis. 1997;56(9):550–7.PubMedCrossRef
5.
go back to reference Ronday HK, Smits HH, Van Muijen GN, Pruszczynski MS, Dolhain RJ, Van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35(5):416–23.PubMedCrossRef Ronday HK, Smits HH, Van Muijen GN, Pruszczynski MS, Dolhain RJ, Van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35(5):416–23.PubMedCrossRef
6.
go back to reference Wallberg-Jonsson S, Rantapaa-Dahlqvist S, Nordmark L, Ranby M. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol. 1996;23(10):1704–9.PubMed Wallberg-Jonsson S, Rantapaa-Dahlqvist S, Nordmark L, Ranby M. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol. 1996;23(10):1704–9.PubMed
7.
go back to reference Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis. 1996;55(4):230–6.PubMedCrossRef Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis. 1996;55(4):230–6.PubMedCrossRef
8.
go back to reference Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost. 1992;68(2):180–4.PubMed Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost. 1992;68(2):180–4.PubMed
9.
go back to reference Jin T, Tarkowski A, Carmeliet P, Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther. 2003;5(1):R9–17.PubMedCrossRef Jin T, Tarkowski A, Carmeliet P, Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther. 2003;5(1):R9–17.PubMedCrossRef
10.
go back to reference Kummer JA, Abbink JJ, de Boer JP, Roem D, Nieuwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum. 1992;35(8):884–93.PubMedCrossRef Kummer JA, Abbink JJ, de Boer JP, Roem D, Nieuwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum. 1992;35(8):884–93.PubMedCrossRef
11.
go back to reference Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol. 1993;20(1):91–6.PubMed Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol. 1993;20(1):91–6.PubMed
12.
go back to reference Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34(8):996–1005.PubMedCrossRef Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34(8):996–1005.PubMedCrossRef
13.
go back to reference Carmassi F, De Negri F, Morale M, Puccetti R, Chung SI. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis. Int J Tissue React. 1994;16(2):89–93.PubMed Carmassi F, De Negri F, Morale M, Puccetti R, Chung SI. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis. Int J Tissue React. 1994;16(2):89–93.PubMed
14.
go back to reference Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol. 1997;16(3):254–60.PubMedCrossRef Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol. 1997;16(3):254–60.PubMedCrossRef
15.
go back to reference Barnhart MI, Riddle JM, Bluhm GB, Quintana C. Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis. 1967;26(3):206–18.PubMedCrossRef Barnhart MI, Riddle JM, Bluhm GB, Quintana C. Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis. 1967;26(3):206–18.PubMedCrossRef
16.
go back to reference Clemmensen I, Holund B, Andersen RB. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum. 1983;26(4):479–85.PubMedCrossRef Clemmensen I, Holund B, Andersen RB. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum. 1983;26(4):479–85.PubMedCrossRef
17.
go back to reference Zacharski LR, Brown FE, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155–62.PubMedCrossRef Zacharski LR, Brown FE, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155–62.PubMedCrossRef
18.
go back to reference Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis. 2003;62(12):1135–8.PubMedCrossRef Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis. 2003;62(12):1135–8.PubMedCrossRef
19.
go back to reference Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177–84.PubMed Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177–84.PubMed
20.
go back to reference Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102(1):41–50. doi:10.1172/JCI2312.PubMedCrossRef Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102(1):41–50. doi:10.​1172/​JCI2312.PubMedCrossRef
21.
go back to reference Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007;117(11):3224–35. doi:10.1172/JCI30134.PubMedCrossRef Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007;117(11):3224–35. doi:10.​1172/​JCI30134.PubMedCrossRef
24.
go back to reference Salvi R, Peclat V, So A, Busso N. Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis. Arthritis Res. 2000;2(6):504–12.PubMedCrossRef Salvi R, Peclat V, So A, Busso N. Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis. Arthritis Res. 2000;2(6):504–12.PubMedCrossRef
27.
go back to reference Sagripanti A, Morganti M, Carpi A, Cupisti A, Nicolini A, Barsotti M, et al. Uremic medium increases cytokine-induced PAI-1 secretion by cultured endothelial cells. Biomed Pharmacother. 1998;52(7–8):298–302.PubMedCrossRef Sagripanti A, Morganti M, Carpi A, Cupisti A, Nicolini A, Barsotti M, et al. Uremic medium increases cytokine-induced PAI-1 secretion by cultured endothelial cells. Biomed Pharmacother. 1998;52(7–8):298–302.PubMedCrossRef
28.
go back to reference van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 1990;75(10):1991–8.PubMed van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 1990;75(10):1991–8.PubMed
29.
go back to reference Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175–9. doi:10.1016/j.jaut.2008.07.002.PubMedCrossRef Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175–9. doi:10.​1016/​j.​jaut.​2008.​07.​002.PubMedCrossRef
30.
go back to reference Jin T, Bokarewa M, Amu S, Tarkowski A. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):491–4. doi:2631[pii].PubMed Jin T, Bokarewa M, Amu S, Tarkowski A. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):491–4. doi:2631[pii].PubMed
31.
go back to reference Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis. 2000;59(10):781–7.PubMedCrossRef Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis. 2000;59(10):781–7.PubMedCrossRef
33.
go back to reference Van Ness K, Chobaz-Peclat V, Castellucci M, So A, Busso N. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford). 2002;41(2):136–41.CrossRef Van Ness K, Chobaz-Peclat V, Castellucci M, So A, Busso N. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford). 2002;41(2):136–41.CrossRef
34.
go back to reference Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol. 2001;167(2):1047–52.PubMed Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol. 2001;167(2):1047–52.PubMed
36.
37.
go back to reference Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol. 2002;160(3):917–26.PubMedCrossRef Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol. 2002;160(3):917–26.PubMedCrossRef
38.
go back to reference Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, et al. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther. 2010;12(2):R37. doi:10.1186/ar2946.PubMedCrossRef Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, et al. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther. 2010;12(2):R37. doi:10.​1186/​ar2946.PubMedCrossRef
39.
go back to reference Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol. 2005;166(3):783–92. doi:166/3/783[pii].PubMedCrossRef Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol. 2005;166(3):783–92. doi:166/​3/​783[pii].PubMedCrossRef
40.
go back to reference Calabozo M, Aretxabala I, Alonso-Ruiz A, Perez-Ruiz F, Fraiz E, Ruiz-Lucea E, et al. Intraarticular urokinase: a new drainage technique for synovial effusions with rice bodies. J Rheumatol. 1998;25(2):394–5.PubMed Calabozo M, Aretxabala I, Alonso-Ruiz A, Perez-Ruiz F, Fraiz E, Ruiz-Lucea E, et al. Intraarticular urokinase: a new drainage technique for synovial effusions with rice bodies. J Rheumatol. 1998;25(2):394–5.PubMed
41.
go back to reference Sturrock RD, Watkin C, Williamson T, Dick WC. Intra-articular urokinase in rheumatoid arthritis. Ann Rheum Dis. 1974;33(2):124–5.PubMedCrossRef Sturrock RD, Watkin C, Williamson T, Dick WC. Intra-articular urokinase in rheumatoid arthritis. Ann Rheum Dis. 1974;33(2):124–5.PubMedCrossRef
42.
go back to reference Imiela J, Nosarzewski J, Górski A. Oral heparin in the treatment of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 1995;43(5–6):313–5. Imiela J, Nosarzewski J, Górski A. Oral heparin in the treatment of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 1995;43(5–6):313–5.
Metadata
Title
Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease
Authors
Jakub Kwieciński
Elisabet Josefsson
Tao Jin
Publication date
01-11-2011
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 11/2011
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0363-0

Other articles of this Issue 11/2011

Inflammation Research 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.